JP2011519960A5 - - Google Patents

Download PDF

Info

Publication number
JP2011519960A5
JP2011519960A5 JP2011508768A JP2011508768A JP2011519960A5 JP 2011519960 A5 JP2011519960 A5 JP 2011519960A5 JP 2011508768 A JP2011508768 A JP 2011508768A JP 2011508768 A JP2011508768 A JP 2011508768A JP 2011519960 A5 JP2011519960 A5 JP 2011519960A5
Authority
JP
Japan
Prior art keywords
angiogenin
prophylactic
agent according
muscular dystrophy
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011508768A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011519960A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2009/000602 external-priority patent/WO2009137879A1/en
Publication of JP2011519960A publication Critical patent/JP2011519960A/ja
Publication of JP2011519960A5 publication Critical patent/JP2011519960A5/ja
Pending legal-status Critical Current

Links

JP2011508768A 2008-05-14 2009-05-14 アンギオゲニンを含む経口投与可能な投与形態物及びその使用 Pending JP2011519960A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2008902371A AU2008902371A0 (en) 2008-05-14 Oral preparation
AU2008902371 2008-05-14
PCT/AU2009/000602 WO2009137879A1 (en) 2008-05-14 2009-05-14 Orally administrable dosage forms comprising angiogenin and uses thereof

Publications (2)

Publication Number Publication Date
JP2011519960A JP2011519960A (ja) 2011-07-14
JP2011519960A5 true JP2011519960A5 (enExample) 2012-06-21

Family

ID=41318285

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011508768A Pending JP2011519960A (ja) 2008-05-14 2009-05-14 アンギオゲニンを含む経口投与可能な投与形態物及びその使用

Country Status (14)

Country Link
US (1) US20110262422A1 (enExample)
EP (1) EP2307044A4 (enExample)
JP (1) JP2011519960A (enExample)
KR (1) KR20110033122A (enExample)
CN (1) CN102099050A (enExample)
AU (1) AU2009246052A1 (enExample)
BR (1) BRPI0911958A2 (enExample)
CA (1) CA2724048A1 (enExample)
IL (1) IL209284A0 (enExample)
MX (1) MX2010012438A (enExample)
NZ (1) NZ589306A (enExample)
RU (1) RU2010150934A (enExample)
WO (1) WO2009137879A1 (enExample)
ZA (1) ZA201009004B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101760758B1 (ko) * 2008-05-14 2017-07-24 애그리컬쳐 빅토리아 서비스 피티와이 엘티디 질병 및 장애를 치료하기 위한 안지오게닌 또는 안지오게닌 아고니스트의 이용
CA2818467A1 (en) * 2009-11-18 2011-05-26 Murray Goulburn Co-Operative Co. Limited Recombinant microorganisms
US20120328591A1 (en) * 2009-11-18 2012-12-27 Agriculture Victoria Services Pty Ltd Methods for improving oral delivery
WO2011060489A1 (en) * 2009-11-18 2011-05-26 Murray Goulburn Co-Operative Co. Limited Transgenic non-human animals
WO2011113100A1 (en) * 2010-03-17 2011-09-22 Murray Goulburn Co-Operative Co. Limited Method of treating a bone disorder
AU2013204740C1 (en) * 2012-05-10 2015-10-01 Agriculture Victoria Services Pty Ltd Methods of treating cancer using angiogenin or an angiogenin agonist
WO2014020676A1 (ja) * 2012-07-31 2014-02-06 雪印メグミルク株式会社 新規タンパク質素材
JP6140162B2 (ja) * 2012-07-31 2017-05-31 雪印メグミルク株式会社 骨強化用粉乳組成物及びその製造方法
AU2012386764B2 (en) * 2012-07-31 2016-05-05 Megmilk Snow Brand Co., Ltd. Powdered milk product, and method for producing same
MX2015001340A (es) * 2012-07-31 2015-09-04 Megmilk Snow Brand Co Ltd Producto novedoso de leche fermentada y metodo para preparar el mismo.
KR101996117B1 (ko) * 2012-07-31 2019-07-03 유키지루시 메그밀크 가부시키가이샤 음료 및 그 제조 방법
AU2012386761B2 (en) 2012-07-31 2016-05-05 Megmilk Snow Brand Co., Ltd. Beverage, and method for producing same
KR20150036687A (ko) * 2012-07-31 2015-04-07 유키지루시 메그밀크 가부시키가이샤 치즈류 및 그 제조 방법
AU2012386763B2 (en) 2012-07-31 2016-05-05 Megmilk Snow Brand Co., Ltd. Fermented milk product, and method for producing same
AU2012386758C1 (en) * 2012-07-31 2017-03-30 Megmilk Snow Brand Co., Ltd. Novel protein material
JP2016152809A (ja) * 2016-04-05 2016-08-25 雪印メグミルク株式会社 飲料及びその製造方法
JP6562956B2 (ja) * 2017-02-28 2019-08-21 雪印メグミルク株式会社 飲料及びその製造方法
JP6357266B2 (ja) * 2017-06-07 2018-07-11 雪印メグミルク株式会社 骨疾患の予防又は治療用タンパク質素材
JP6357265B2 (ja) * 2017-06-07 2018-07-11 雪印メグミルク株式会社 骨疾患の予防又は治療用タンパク質素材

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2947657B2 (ja) * 1991-02-27 1999-09-13 森永乳業株式会社 神経成長因子産生促進剤
JP3929088B2 (ja) * 1996-06-20 2007-06-13 雪印乳業株式会社 骨形成促進及び骨吸収防止剤
JPH10139682A (ja) * 1996-11-14 1998-05-26 Mitsubishi Chem Corp 骨吸収促進剤
CN1761463A (zh) * 2003-03-17 2006-04-19 日本烟草产业株式会社 提高s-[2-([[1-(2-乙基丁基)环己基]羰基]氨基)苯基]-2-甲基丙硫代酸酯口服生物利用度的方法
JP4698935B2 (ja) * 2003-05-07 2011-06-08 雪印乳業株式会社 皮膚コラーゲン産生促進剤
WO2004106491A2 (en) * 2003-05-22 2004-12-09 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Angiogenin-based hiv-1 therapies
US20050180957A1 (en) * 2004-01-16 2005-08-18 Scharp David W. Method of using fibrin-bound angiogenic factors to stimulate vascularization of transplant site of encapsulated cells
GB0425625D0 (en) * 2004-11-22 2004-12-22 Royal College Of Surgeons Ie Treatment of disease
WO2007023479A2 (en) * 2005-08-23 2007-03-01 Royal College Of Surgeons In Ireland Treatment of central nervous system injury
US8021659B2 (en) * 2006-04-28 2011-09-20 Naidu Lp Coenzyme Q10, lactoferrin and angiogenin compositions and uses thereof
US20070275036A1 (en) * 2006-05-18 2007-11-29 Celldyne Biopharma, Llc Avian follistatin product
US8551547B2 (en) * 2006-11-10 2013-10-08 Murray Goulburn Co-Operative Co., Limited Process for the preparation of angiogenin
KR101760758B1 (ko) * 2008-05-14 2017-07-24 애그리컬쳐 빅토리아 서비스 피티와이 엘티디 질병 및 장애를 치료하기 위한 안지오게닌 또는 안지오게닌 아고니스트의 이용

Similar Documents

Publication Publication Date Title
JP2011519960A5 (enExample)
RU2010150934A (ru) Пероральный препарат
RU2010150931A (ru) Применение ангиогенина или агонистов ангиогенина для лечения заболеваний и нарушений
WO2004052371A3 (en) Cyclic quinoline compounds for use in mch receptor related disorders
JP2006502162A5 (enExample)
AU2003273967A1 (en) Use of indoleacetic acid derivatives which increase the serum igf-1 level for the preparation of a therapeutical composition for treatment of various diseases
JP2005534616A5 (enExample)
US20090035306A1 (en) Quinazolinone modulators of tgr5
CN110869024A (zh) 多生物剂及其使用方法
WO2007050726A3 (en) Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists
NO20074117L (no) Fremgangsmater og sammensetninger for a behandle diabetes, metabolske sykdommer og tilstander
BRPI0418079A (pt) composto, composição farmacêutica, e, usos de uma composição e de um composto
JP2009286804A5 (enExample)
EP2117559A2 (en) Pharmaceutical composition for the treatment of il-8 mediated diseases
JP2017538705A5 (enExample)
MX2011013507A (es) Nuevos agonistas del gpr 119.
WO2006042152A3 (en) Vasoactive intestinal polypeptide pharmaceuticals
JP2014508758A5 (enExample)
EP3081228B1 (en) Irisin for care and prevention of osteoporosis
JP2007505883A5 (enExample)
RU2013119595A (ru) Низкодозовая фармацевтическая композиция
TW200306294A (en) Helicobacter infection treatment
JP2013511287A5 (enExample)
WO2008019062A3 (en) Polypeptide derivatives of parathyroid hormone (pth)
CN101530617A (zh) 一种含ppar调节剂和锶盐的药物组合物